Centrus Signs Definitive $900M DOE HALEU Contract, Accelerating Enrichment Expansion

What happened

Centrus Energy reported second-quarter 2026 revenue of $176.1 million, up 14% year-over-year, and non-GAAP adjusted net income of $38.7 million, while converting the previously non-definitive $900 million HALEU task order into a signed contract with the U.S. Department of Energy. The company also signed its first large-scale commercial HALEU supply agreement with potential prepayments, selected Geiger Brothers as construction contractor for the Piketon expansion, and raised its full-year hiring guidance. Contingent LEU and HALEU enrichment backlog grew to $3.0 billion, though a substantial portion remains dependent on securing further public and private investment. Operating cash flow remained negative at $35.1 million in the first quarter as expansion spending ramps, with the company expecting to complete its first new centrifuge in Oak Ridge by year-end 2026. Together, these steps shift the narrative from contract negotiation to execution on funded, milestone-based scale-up.

Implication

With the $900 million DOE contract now signed, Centrus gains contractual visibility on milestone payments, directly addressing the master report’s key trigger for upgrading the thesis. The first commercial HALEU supply agreement, particularly if it includes prepayments, could provide additional non-dilutive funding to offset heavy expansion capex. However, the FY2027 DOE budget still lacks cascade operations funding beyond June 2026, and large contingent backlog requires financing that remains unsecured. The valuation at roughly 60 times earnings leaves little room for misses, so monitoring realized cost savings and conversion of 'identified' savings into actual cost-to-complete reductions will be critical. At these levels, the stock is fairly priced for a smooth ramp, but the risk-reward now tilts favorably as execution milestones become fundable.

Thesis delta

The prior 'WAIT' rating hinged on the absence of a definitive DOE deal; the signed $900 million contract clears that hurdle, upgrading the thesis to a 'BUY' at current levels with a 6-12 month window to monitor milestone execution. Key remaining risks include operating continuity past June 2026 and the need to convert cost savings from 'identified' to realized. The first commercial HALEU prepayment agreement further de-risks the funding path.